Intensity Therapeutics (INTS) Other Accumulated Expenses (2022 - 2023)
Intensity Therapeutics' (INTS) quarterly Other Accumulated Expenses came in at $14367.0 in Q3 2023, up 349.81% on a QoQ basis from $3194.0 in Q2 2023.
Intensity Therapeutics (INTS) Other Accumulated Expenses (2022 - 2023) Analysis & Trends
Intensity Therapeutics (INTS) has 2 years of Other Accumulated Expenses data on file, last reported at $14367.0 in Q3 2023.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $14367.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $14367.0 (changed N/A YoY) and the FY2022 annual result came in at $2269.0, changed N/A from the prior year.
- Other Accumulated Expenses advanced to $14367.0 in Q3 2023, from $3194.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $14367.0 in Q3 2023 to a low of $2269.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 14,367.00 |
| Jun 30, 2023 | 3,194.00 |
| Dec 31, 2022 | 2,269.00 |